Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

Phase 2 Recruiting 72 enrolled Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.

Timeline

Start: 2025-08-08
Primary completion: 2025-12
Completion: 2026-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HL-1186	Unknown	—	Oral

Indications

No indication recorded.